Compare Stocks

Date Range: 

 CortexymeCurisCoherus BioSciencesVaxcyteMesoblast
SymbolNASDAQ:CRTXNASDAQ:CRISNASDAQ:CHRSNASDAQ:PCVXNASDAQ:MESO
Price Information
Current Price$36.35$9.83$14.08$17.34$6.75
52 Week RangeHoldBuyBuyBuyHold
MarketRank™
Overall Score1.61.31.41.71.4
Analysis Score3.13.53.43.53.2
Community Score2.62.62.52.93.1
Dividend Score0.00.00.00.00.0
Ownership Score2.50.00.01.70.0
Earnings & Valuation Score0.00.61.30.60.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyHold
Consensus Price Target$50.00$14.60$25.00$48.00$14.55
% Upside from Price Target37.55% upside48.52% upside77.56% upside176.82% upside115.56% upside
Trade Information
Market Cap$1.08 billion$899.63 million$1.07 billion$890.50 million$875.74 million
Beta0.953.291.57N/A3.71
Average Volume280,6321,960,1081,230,471372,785544,535
Sales & Book Value
Annual RevenueN/A$10 million$356.07 millionN/A$32.16 million
Price / SalesN/A89.963.00N/A27.23
CashflowN/AN/A$1.05 per shareN/AN/A
Price / CashN/AN/A13.36N/AN/A
Book Value$4.30 per share($1.02) per share$1.50 per shareN/A$4.70 per share
Price / BookN/A-9.649.39N/A1.44
Profitability
Net Income$-36,980,000.00$-32,140,000.00$89.83 million$-50,270,000.00$-77,940,000.00
EPS($1.94)($0.86)$1.23N/A($0.74)
Trailing P/E RatioN/AN/A6.900.00N/A
Forward P/E RatioN/AN/A16.00N/AN/A
P/E GrowthN/AN/A9.34N/AN/A
Net MarginsN/A-279.33%33.06%N/A-591.00%
Return on Equity (ROE)-37.78%N/A90.98%N/A-18.69%
Return on Assets (ROA)-35.24%-81.32%27.33%N/A-13.85%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A1.58%N/A0.10%
Current Ratio8.71%3.10%5.45%10.12%1.32%
Quick Ratio8.71%3.10%5.18%10.12%1.32%
Ownership Information
Institutional Ownership Percentage55.48%34.66%N/A74.08%2.80%
Insider Ownership Percentage19.80%7.34%15.86%N/A18.80%
Miscellaneous
Employees372831058102
Shares Outstanding29.59 million91.52 million75.75 million51.36 million129.74 million
Next Earnings Date8/16/2021 (Estimated)5/12/2021 (Confirmed)8/5/2021 (Estimated)7/5/2021 (Estimated)5/26/2021 (Estimated)
OptionableNot OptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Regenerative Therapies for Osteoarthritis Market SWOT Analysis including key players Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma – Jumbo News - Jumbo NewsRegenerative Therapies for Osteoarthritis Market SWOT Analysis including key players Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma – Jumbo News - Jumbo News
jumbonews.co.uk - May 11 at 2:55 PM
Adipose Derived Stem Cell Therapy Market – Major Technology Giants in Buzz Again | AlloCure, Antria, Celgene Corporation, Cellleris – The Manomet Current - The Manomet CurrentAdipose Derived Stem Cell Therapy Market – Major Technology Giants in Buzz Again | AlloCure, Antria, Celgene Corporation, Cellleris – The Manomet Current - The Manomet Current
manometcurrent.com - May 11 at 2:55 PM
Mesoblast (NASDAQ:MESO) Hits New 52-Week Low at $6.88Mesoblast (NASDAQ:MESO) Hits New 52-Week Low at $6.88
americanbankingnews.com - May 11 at 10:39 AM
Why does the Mesoblast (ASX:MSB) share price keep falling? - The Motley Fool AustraliaWhy does the Mesoblast (ASX:MSB) share price keep falling? - The Motley Fool Australia
fool.com.au - May 11 at 9:51 AM
Mesoblast (NASDAQ:MESO) Shares Gap Up to $6.98Mesoblast (NASDAQ:MESO) Shares Gap Up to $6.98
americanbankingnews.com - May 10 at 2:45 PM
MANA Therapeutics Appoints Arthur Hurwitz as Chief Scientific Officer - Joplin GlobeMANA Therapeutics Appoints Arthur Hurwitz as Chief Scientific Officer - Joplin Globe
joplinglobe.com - May 10 at 10:22 AM
Rheumatoid Arthritis Stem Cell Therapy Market Is Booming Worldwide | Mesoblast, Roslin Cells, Regeneus – Jumbo News - Jumbo NewsRheumatoid Arthritis Stem Cell Therapy Market Is Booming Worldwide | Mesoblast, Roslin Cells, Regeneus – Jumbo News - Jumbo News
jumbonews.co.uk - May 10 at 10:22 AM
Autologous Stem Cell Based Therapies Market 2021 Global Outlook – Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics – The Shotcaller - The ShotcallerAutologous Stem Cell Based Therapies Market 2021 Global Outlook – Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics – The Shotcaller - The Shotcaller
theshotcaller.net - May 9 at 7:31 AM
Stocks That Hit 52-Week Lows On Friday Fridays morning session saw 17 companies set new - BenzingaStocks That Hit 52-Week Lows On Friday Friday's morning session saw 17 companies set new - Benzinga
benzinga.com - May 8 at 12:25 AM
Asia-Pacific (APAC) Tissue Regenaration Market by Type, Application, Element – Global Trends and For - PharmiWeb.comAsia-Pacific (APAC) Tissue Regenaration Market by Type, Application, Element – Global Trends and For - PharmiWeb.com
pharmiweb.com - May 6 at 1:21 PM
Analysts Offer Predictions for Mesoblast Limiteds FY2022 Earnings (NASDAQ:MESO)Analysts Offer Predictions for Mesoblast Limited's FY2022 Earnings (NASDAQ:MESO)
americanbankingnews.com - May 6 at 11:12 AM
15 recent ASC exec moves - Beckers ASC Review15 recent ASC exec moves - Becker's ASC Review
beckersasc.com - May 5 at 5:20 PM
Remestemcel-L reduces ARDS mortality in those under 65 years old - European Pharmaceutical ReviewRemestemcel-L reduces ARDS mortality in those under 65 years old - European Pharmaceutical Review
europeanpharmaceuticalreview.com - May 4 at 12:52 PM
Investors Buy Large Volume of Call Options on Mesoblast (NASDAQ:MESO)Investors Buy Large Volume of Call Options on Mesoblast (NASDAQ:MESO)
americanbankingnews.com - May 4 at 6:56 AM
Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength? - Yahoo FinanceStrength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength? - Yahoo Finance
finance.yahoo.com - May 3 at 3:22 PM
Is Mesoblast limited (MESO) Stock About to Get Hot Monday? - InvestorsObserverIs Mesoblast limited (MESO) Stock About to Get Hot Monday? - InvestorsObserver
investorsobserver.com - May 3 at 3:22 PM
Mesoblast (NASDAQ:MESO) Sets New 52-Week Low at $7.21Mesoblast (NASDAQ:MESO) Sets New 52-Week Low at $7.21
americanbankingnews.com - May 3 at 11:46 AM
Stem Cells Market Size 2021 | Is Expected to Showcase Considerable Growth by Reaching USD 27.65 Billion by 2028 While Exhibiting a CAGR of 12.8% between 2021 and 2028 - StockhouseStem Cells Market Size 2021 | Is Expected to Showcase Considerable Growth by Reaching USD 27.65 Billion by 2028 While Exhibiting a CAGR of 12.8% between 2021 and 2028 - Stockhouse
stockhouse.com - May 3 at 10:22 AM
Global Autologous Stem Cell Based Therapies Market Revenue 2021 | Regeneus, Mesoblast, Pluristem Therapeutics Inc – Jumbo News - Jumbo NewsGlobal Autologous Stem Cell Based Therapies Market Revenue 2021 | Regeneus, Mesoblast, Pluristem Therapeutics Inc – Jumbo News - Jumbo News
jumbonews.co.uk - May 3 at 10:22 AM
Umbilical Cord Blood (UCB) Stem Cell: Market – Recent Industry Developments and Growth Strategies Adopted by Top Players | Mesoblast, Mesoblast Limited, California Stem Cell, Pluristem Therapeutics – Good News Gum - Good News GumUmbilical Cord Blood (UCB) Stem Cell: Market – Recent Industry Developments and Growth Strategies Adopted by Top Players | Mesoblast, Mesoblast Limited, California Stem Cell, Pluristem Therapeutics – Good News Gum - Good News Gum
goodnewsgum.com - May 3 at 10:22 AM
REMESTEMCEL-L REDUCES MORTALITY IN PATIENTS LESS THAN 65 YEARS OLD WITH MODERATE/SEVERE COVID-19 ARDS: TOPLINE 60-DAY RESULTS FROM RANDOMIZED CONTROLLED TRIAL - marketscreener.comREMESTEMCEL-L REDUCES MORTALITY IN PATIENTS LESS THAN 65 YEARS OLD WITH MODERATE/SEVERE COVID-19 ARDS: TOPLINE 60-DAY RESULTS FROM RANDOMIZED CONTROLLED TRIAL - marketscreener.com
marketscreener.com - May 3 at 10:22 AM
Mesoblasts selective disclosure continues - The Australian Financial ReviewMesoblast's selective disclosure continues - The Australian Financial Review
afr.com - May 3 at 10:22 AM
Cord Blood Stem Cells Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited, Opexa Therapeutics Inc., etc. - Good News GumCord Blood Stem Cells Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited, Opexa Therapeutics Inc., etc. - Good News Gum
goodnewsgum.com - May 2 at 1:08 PM
Stem Cells Market : Growth Factors and Competitive Players till 2026| CELGENE CORPORATION, ReNeuron Group plc, Virgin Health Bank , Biovault family, Precious Cells International Ltd, Mesoblast Ltd - Good News GumStem Cells Market : Growth Factors and Competitive Players till 2026| CELGENE CORPORATION, ReNeuron Group plc, Virgin Health Bank , Biovault family, Precious Cells International Ltd, Mesoblast Ltd - Good News Gum
goodnewsgum.com - April 30 at 11:49 PM
Mesoblast (ASX:MSB) study finds drug reduces mortality in COVID-19 ARDS patients under 65 - The Market HeraldMesoblast (ASX:MSB) study finds drug reduces mortality in COVID-19 ARDS patients under 65 - The Market Herald
themarketherald.com.au - April 30 at 11:49 PM
DateCompanyBrokerageAction
2/16/2021CortexymeJefferies Financial GroupDowngrade
12/11/2020CortexymeSmith Barney CitigroupInitiated Coverage
12/11/2020CortexymeCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
12/7/2020CortexymeBank of AmericaUpgrade
9/24/2020CortexymeLifesci CapitalReiterated Rating
6/24/2020CortexymeHC WainwrightInitiated Coverage
5/13/2020CortexymeCanaccord GenuityReiterated Rating
6/3/2019CortexymeCredit Suisse GroupInitiated Coverage
6/3/2019CortexymeJMP SecuritiesInitiated Coverage
3/30/2021CurisB. RileyInitiated Coverage
3/17/2021CurisJonestradingBoost Price Target
12/16/2020CurisCantor FitzgeraldBoost Price Target
7/29/2020CurisLaidlawInitiated Coverage
9/25/2018CurisCowenReiterated Rating
8/3/2018CurisSunTrust BanksLower Price Target
5/7/2021Coherus BioSciencesMaxim GroupInitiated Coverage
11/19/2020Coherus BioSciencesMizuhoLower Price Target
2/6/2020Coherus BioSciencesJPMorgan Chase & Co.Boost Price Target
8/12/2019Coherus BioSciencesBarclaysSet Price Target
8/14/2020VaxcyteNeedham & Company LLCReiterated Rating
12/4/2020MesoblastChardan CapitalDowngrade
10/22/2020MesoblastRoyal Bank of CanadaInitiated Coverage
5/28/2020MesoblastLADENBURG THALM/SH SHBoost Price Target
12/19/2019MesoblastDawson JamesInitiated Coverage
9/10/2019MesoblastOppenheimerSet Price Target
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.